IO Biotech Faces Downgrades as Analysts Shift Ratings to “Sell”

IO Biotech (NASDAQ:IOBT) has experienced a downgrade in its stock ratings, with analysts at Wall Street Zen reducing their assessment from “hold” to “sell.” This change, announced in a report on Monday, reflects a growing concern among financial experts regarding the company’s performance and future prospects.

Recent Analyst Ratings Shift

Several other financial institutions have also reevaluated their positions on IO Biotech. On September 30, 2023, Morgan Stanley downgraded the company from an “overweight” rating to an “equal weight” rating, indicating a more cautious approach. Similarly, Weiss Ratings maintained a “sell (e+)” rating, while HC Wainwright shifted its recommendation from “buy” to “neutral” on the same day.

Cowen also altered its stance, giving IO Biotech a “hold” rating. Notably, the consensus among analysts is somewhat mixed, with one investment analyst recommending a “buy” rating, four suggesting a “hold,” and one advocating for a “sell.” As per data from MarketBeat.com, the average rating for IO Biotech currently stands at “hold,” with an average price target of $6.33.

Financial Performance and Institutional Interest

IO Biotech released its latest earnings report on November 14, 2023, revealing earnings per share (EPS) of ($0.28), surpassing the consensus estimate of ($0.31). Looking ahead, analysts predict that the company will report an EPS of ($1.35) for the current fiscal year, highlighting ongoing challenges.

Institutional investors have been active in the market regarding IO Biotech, with several firms acquiring shares recently. Notable transactions include Jane Street Group LLC, which purchased a stake valued at approximately $26,000 in the first quarter, and NewEdge Advisors LLC, which bought shares worth $34,000 in the second quarter. Marex Group plc also acquired shares worth $63,000 during the same period.

Boothbay Fund Management LLC and Millennium Management LLC made more substantial investments, with respective stakes valued at $215,000 and $506,000. Currently, institutional investors own 54.76% of IO Biotech’s stock, indicating significant interest in the company despite its recent struggles.

Headquartered in Copenhagen, Denmark, IO Biotech focuses on developing innovative immuno-oncology therapies. Its proprietary platform aims to activate and sustain anti-tumor immune responses through PD-L1 immune checkpoint targeting. The company’s lead candidate, IO-VAC(R), is a peptide-based cancer vaccine aimed at eliciting durable T-cell responses against PD-L1–expressing tumors.

Since its establishment in 2013, IO Biotech has advanced IO-VAC(R) into multiple clinical trials, including Phase II studies involving patients with metastatic melanoma. As the company navigates recent market challenges, its performance will be closely monitored by investors and analysts alike.